Clinical Trials · NCT04276597

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

WithdrawnPhase 2Octreotide (Prohibited)
Phase
Phase 2
Recruitment status
Withdrawn
Sponsor
Excel Diagnostics and Nuclear Oncology Center
Enrollment
0
Start date
Mar 2020
Locations
1 site, United States
Primary endpoint
Assessment of the overall response rate
View Octreotide compound reference